New data show commercially insured patients face  increasingly high cost sharing for brand medicines

New data show deductibles and coinsurance result in high out-of-pocket spending for commercially insured patients taking brand medicines.IQVIA analyzed trends in cost sharing across seven therapy areas and found that anywhere from 44% to 95% of patients ’ total out-of-pocket spending for brand medicines in 2019 was due to deductibles and coinsurance. Compared to patients who only paid copays for brand medicines, patients with deductibles or coinsurance had significantly higher annual out-of-pocket spending across all seven therapeutic areas. In f act, for patients with complex conditions, like cancer and HIV, spending was as much as 25 to 30 times higher.

Source: The Catalyst - July 30, 2020 Category: Pharmaceuticals Authors: Gabby Migliara Tags: Drug Cost Out-of-Pocket Costs Let's Talk About Cost Source Type: news